Price/FCF Ratio: 41.33
Is the Price/FCF ratio high or low?
The Price/FCF ratio of 41.33 is 16% below its 5-year average of 49.28, near the low end of its 5-year range (25.21–89.20).
7.91% above its 12-month average of 38.30.
TECH Price/FCF Ratio Chart
TECH Average Price/FCF Ratio Chart
TECH Current vs Average Price/FCF Ratio Chart
TECH Price/FCF Ratio Metrics
PRICE/FCF RATIO
41.33
PRICE/FCF RATIO AVG TTM
38.30
PRICE/FCF RATIO AVG 3Y
44.71
PRICE/FCF RATIO AVG 5Y
47.96
PRICE/FCF RATIO AVG 10Y
47.26
PRICE/FCF RATIO AVG 15Y
40.37
PRICE/FCF RATIO AVG 20Y
36.48
CURRENT VS TTM AVG
+7.91%
CURRENT VS 3Y AVG
-7.56%
CURRENT VS 5Y AVG
-13.83%
CURRENT VS 10Y AVG
-12.55%
CURRENT VS 15Y AVG
+2.39%
CURRENT VS 20Y AVG
+13.30%
TECH Competitors' Price/FCF Ratio
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 41.33 | 38.30 | 44.71 | 47.96 |
| Insulet Corp. (PODD)vs › | $10.96B | 26.95 | 49.57 | 74.36 | 74.36 |
| Baxter International Inc. (BAX)vs › | $11.38B | 15.90 | 37.19 | 30.84 | 30.16 |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | 43.90 | 28.42 | 49.84 | 32.65 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 17.86 | 17.13 | 29.64 | 17.62 |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.20B | 26.61 | 16.61 | 22.61 | 28.22 |
| Tempus AI, Inc. (TEM)vs › | $9.80B | N/A | N/A | N/A | N/A |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 22.88 | 20.93 | 20.46 | 19.49 |
| Revvity, Inc. (RVTY)vs › | $12.61B | 25.60 | 22.01 | 204.31 | 127.28 |
| Align Technology, Inc. (ALGN)vs › | $12.78B | 18.34 | 19.00 | 30.69 | 40.18 |
Free Cash Flow Valuation
P/FCF Ratio
41.3
FCF Yield
2.42%
Price/FCF Ratio Formula & Definition
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Price/FCF Ratio FAQ
- What is the Price/FCF ratio for Bio-Techne Corporation (TECH)?
- The Price/FCF ratio for TECH stock is 41.33.
- Is Bio-Techne Corporation's Price/FCF ratio high or low?
- The Price/FCF ratio of 41.33 is 16% below its 5-year average of 49.28, near the low end of its 5-year range (25.21–89.20).
- What is the TTM average Price/FCF ratio for Bio-Techne Corporation (TECH)?
- The TTM average Price/FCF ratio for TECH stock is 38.30.
- What is the 3Y average Price/FCF ratio for Bio-Techne Corporation (TECH)?
- The 3Y average Price/FCF ratio for TECH stock is 44.71.
- What is the 5Y average Price/FCF ratio for Bio-Techne Corporation (TECH)?
- The 5Y average Price/FCF ratio for TECH stock is 47.96.
- What is the 10Y average Price/FCF ratio for Bio-Techne Corporation (TECH)?
- The 10Y average Price/FCF ratio for TECH stock is 47.26.
- What is the 15Y average Price/FCF ratio for Bio-Techne Corporation (TECH)?
- The 15Y average Price/FCF ratio for TECH stock is 40.37.
- What is the 20Y average Price/FCF ratio for Bio-Techne Corporation (TECH)?
- The 20Y average Price/FCF ratio for TECH stock is 36.48.
TECH Price/FCF Ratio History
| DATE | PRICE/FCF RATIO |
|---|---|
| 2026-06-26 | 41.33 |
| 2026-06-25 | 41.16 |
| 2026-06-24 | 34.28 |
| 2026-06-23 | 32.75 |
| 2026-06-22 | 32.37 |
| 2026-06-18 | 33.73 |
| 2026-06-17 | 32.02 |
| 2026-06-16 | 32.62 |
| 2026-06-15 | 32.70 |
| 2026-06-12 | 31.44 |
| 2026-06-11 | 31.45 |
| 2026-06-10 | 30.56 |
| 2026-06-09 | 31.67 |
| 2026-06-08 | 30.65 |
| 2026-06-05 | 30.27 |
| 2026-06-04 | 30.96 |
| 2026-06-03 | 29.60 |
| 2026-06-02 | 28.97 |
| 2026-06-01 | 29.57 |
| 2026-05-29 | 30.08 |
| 2026-05-28 | 29.60 |
| 2026-05-27 | 27.99 |
| 2026-05-26 | 27.93 |
| 2026-05-22 | 28.06 |
| 2026-05-21 | 27.58 |
| 2026-05-20 | 27.19 |
| 2026-05-19 | 26.47 |
| 2026-05-18 | 25.86 |
| 2026-05-15 | 25.21 |
| 2026-05-14 | 26.04 |
| 2026-05-13 | 26.13 |
| 2026-05-12 | 27.60 |
| 2026-05-11 | 27.60 |
| 2026-05-08 | 28.15 |
| 2026-05-07 | 29.64 |
| 2026-05-06 | 27.60 |
| 2026-05-05 | 39.90 |
| 2026-05-04 | 38.54 |
| 2026-05-01 | 38.73 |
| 2026-04-30 | 38.94 |
| 2026-04-29 | 36.57 |
| 2026-04-28 | 37.67 |
| 2026-04-27 | 38.80 |
| 2026-04-24 | 38.15 |
| 2026-04-23 | 36.75 |
| 2026-04-22 | 41.24 |
| 2026-04-21 | 42.01 |
| 2026-04-20 | 42.65 |
| 2026-04-17 | 41.70 |
| 2026-04-16 | 40.38 |
| 2026-04-15 | 41.18 |
| 2026-04-14 | 41.29 |
| 2026-04-13 | 40.50 |
| 2026-04-10 | 39.10 |
| 2026-04-09 | 39.12 |
| 2026-04-08 | 38.87 |
| 2026-04-07 | 37.89 |
| 2026-04-06 | 37.87 |
| 2026-04-02 | 37.40 |
| 2026-04-01 | 37.65 |
| 2026-03-31 | 36.79 |
| 2026-03-30 | 36.63 |
| 2026-03-27 | 35.87 |
| 2026-03-26 | 37.10 |
| 2026-03-25 | 37.09 |
| 2026-03-24 | 36.91 |
| 2026-03-23 | 36.61 |
| 2026-03-20 | 36.24 |
| 2026-03-19 | 36.32 |
| 2026-03-18 | 35.77 |
| 2026-03-17 | 35.94 |
| 2026-03-16 | 34.36 |
| 2026-03-13 | 35.80 |
| 2026-03-12 | 36.23 |
| 2026-03-11 | 37.75 |
| 2026-03-10 | 37.18 |
| 2026-03-09 | 38.63 |
| 2026-03-06 | 37.94 |
| 2026-03-05 | 39.34 |
| 2026-03-04 | 40.72 |
| 2026-03-03 | 40.12 |
| 2026-03-02 | 40.70 |
| 2026-02-27 | 41.53 |
| 2026-02-26 | 40.77 |
| 2026-02-25 | 40.74 |
| 2026-02-24 | 40.55 |
| 2026-02-23 | 38.55 |
| 2026-02-20 | 40.49 |
| 2026-02-19 | 41.01 |
| 2026-02-18 | 41.77 |
| 2026-02-17 | 41.18 |
| 2026-02-13 | 42.19 |
| 2026-02-12 | 41.91 |
| 2026-02-11 | 44.67 |
| 2026-02-10 | 45.62 |
| 2026-02-09 | 46.10 |
| 2026-02-06 | 47.01 |
| 2026-02-05 | 46.36 |
| 2026-02-04 | 48.34 |
| 2026-02-03 | 45.10 |
| 2026-02-02 | 45.54 |
| 2026-01-30 | 44.73 |
| 2026-01-29 | 44.65 |
| 2026-01-28 | 45.75 |
| 2026-01-27 | 47.62 |
| 2026-01-26 | 47.20 |
| 2026-01-23 | 47.57 |
| 2026-01-22 | 48.61 |
| 2026-01-21 | 49.81 |
| 2026-01-20 | 48.55 |
| 2026-01-16 | 47.92 |
| 2026-01-15 | 48.82 |
| 2026-01-14 | 47.73 |
| 2026-01-13 | 46.31 |
| 2026-01-12 | 46.45 |
| 2026-01-09 | 45.85 |
| 2026-01-08 | 45.07 |
| 2026-01-07 | 45.40 |
| 2026-01-06 | 45.56 |
| 2026-01-05 | 43.99 |
| 2026-01-02 | 41.63 |
| 2025-12-31 | 41.04 |
| 2025-12-30 | 41.26 |
| 2025-12-29 | 41.34 |
| 2025-12-26 | 41.33 |
| 2025-12-24 | 41.31 |
| 2025-12-23 | 41.35 |
| 2025-12-22 | 41.15 |
| 2025-12-19 | 40.67 |
| 2025-12-18 | 39.85 |
| 2025-12-17 | 39.77 |
| 2025-12-16 | 40.09 |
| 2025-12-15 | 40.96 |
| 2025-12-12 | 40.83 |
| 2025-12-11 | 42.05 |
| 2025-12-10 | 42.45 |
| 2025-12-09 | 41.05 |
| 2025-12-08 | 42.07 |
| 2025-12-05 | 43.04 |
| 2025-12-04 | 44.34 |
| 2025-12-03 | 44.54 |
| 2025-12-02 | 43.93 |
| 2025-12-01 | 44.50 |
| 2025-11-28 | 45.02 |
| 2025-11-26 | 45.10 |
| 2025-11-25 | 45.95 |
| 2025-11-24 | 44.31 |
| 2025-11-21 | 42.94 |
| 2025-11-20 | 40.99 |
| 2025-11-19 | 40.34 |
| 2025-11-18 | 40.58 |
| 2025-11-17 | 40.90 |
| 2025-11-14 | 41.44 |
| 2025-11-13 | 42.40 |
| 2025-11-12 | 42.85 |
| 2025-11-11 | 41.30 |
| 2025-11-10 | 40.10 |
| 2025-11-07 | 40.06 |
| 2025-11-06 | 40.60 |
| 2025-11-05 | 41.83 |
| 2025-11-04 | 37.10 |
| 2025-11-03 | 37.19 |
| 2025-10-31 | 37.99 |
| 2025-10-30 | 37.01 |
| 2025-10-29 | 37.65 |
| 2025-10-28 | 38.82 |
| 2025-10-27 | 39.01 |
| 2025-10-24 | 40.02 |
| 2025-10-23 | 40.11 |
| 2025-10-22 | 38.73 |
| 2025-10-21 | 38.53 |
| 2025-10-20 | 37.97 |
| 2025-10-17 | 37.56 |
| 2025-10-16 | 37.40 |
| 2025-10-15 | 36.17 |
| 2025-10-14 | 35.98 |
| 2025-10-13 | 36.21 |
| 2025-10-10 | 35.61 |
| 2025-10-09 | 36.37 |
| 2025-10-08 | 36.77 |
| 2025-10-07 | 35.94 |
| 2025-10-06 | 37.59 |
| 2025-10-03 | 38.22 |
| 2025-10-02 | 37.70 |
| 2025-10-01 | 36.38 |
| 2025-09-30 | 33.77 |
| 2025-09-29 | 31.71 |
| 2025-09-26 | 31.48 |
| 2025-09-25 | 30.65 |
| 2025-09-24 | 31.10 |
| 2025-09-23 | 32.13 |
| 2025-09-22 | 32.20 |
| 2025-09-19 | 32.27 |
| 2025-09-18 | 32.17 |
| 2025-09-17 | 31.28 |
| 2025-09-16 | 31.44 |
| 2025-09-15 | 31.34 |
| 2025-09-12 | 31.12 |
| 2025-09-11 | 32.30 |
| 2025-09-10 | 30.94 |
| 2025-09-09 | 32.91 |
| 2025-09-08 | 32.85 |
| 2025-09-05 | 33.03 |
| 2025-09-04 | 32.13 |
| 2025-09-03 | 32.38 |
| 2025-09-02 | 32.43 |
| 2025-08-29 | 33.17 |
| 2025-08-28 | 32.98 |
| 2025-08-27 | 34.13 |
| 2025-08-26 | 34.48 |
| 2025-08-25 | 34.43 |
| 2025-08-22 | 34.66 |
| 2025-08-21 | 38.88 |
| 2025-08-20 | 39.12 |
| 2025-08-19 | 39.51 |
| 2025-08-18 | 38.37 |
| 2025-08-15 | 38.59 |
| 2025-08-14 | 38.69 |
| 2025-08-13 | 39.39 |
| 2025-08-12 | 38.04 |
| 2025-08-11 | 36.11 |
| 2025-08-08 | 36.30 |
| 2025-08-07 | 36.11 |
| 2025-08-06 | 35.91 |
| 2025-08-05 | 39.34 |
| 2025-08-04 | 39.51 |
| 2025-08-01 | 39.52 |
| 2025-07-31 | 39.41 |
| 2025-07-30 | 41.55 |
| 2025-07-29 | 41.67 |
| 2025-07-28 | 42.16 |
| 2025-07-25 | 42.32 |
| 2025-07-24 | 42.10 |
| 2025-07-23 | 39.82 |
| 2025-07-22 | 38.25 |
| 2025-07-21 | 36.19 |
| 2025-07-18 | 37.45 |
| 2025-07-17 | 38.37 |
| 2025-07-16 | 37.29 |
| 2025-07-15 | 37.02 |
| 2025-07-14 | 37.89 |
| 2025-07-11 | 38.98 |
| 2025-07-10 | 39.18 |
| 2025-07-09 | 37.86 |
| 2025-07-08 | 37.93 |
| 2025-07-07 | 37.11 |
| 2025-07-03 | 38.26 |
| 2025-07-02 | 38.29 |
| 2025-07-01 | 37.50 |
| 2025-06-30 | 37.04 |
| 2025-06-27 | 37.32 |
| 2025-06-26 | 38.02 |
| 2025-06-25 | 37.36 |
| 2025-06-24 | 36.00 |
| 2025-06-23 | 35.50 |
| 2025-06-20 | 35.92 |
| 2025-06-18 | 36.09 |
| 2025-06-17 | 35.64 |
| 2025-06-16 | 37.17 |
| 2025-06-13 | 36.37 |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman